A French limited liability company with capital of €1,012,600, AdGeniX was created in 1994 to provide innovative solutions in life sciences and healthcare.
Blood-test screening for trisomy 21 (Down syndrome) in pregnant women, known as non-invasive prenatal testing (NIPT), has been reimbursed since January 2019. AdGeniX offers the IONA screening test, developed by Yourgene Health and the first NIPT to have CE-IVD certification.
AdGeniX also offers laboratory equipment and reagents for cell culture, molecular biology and cytogenetics.
A partner of Faster srl for 25 years, AdGeniX offers the most extensive range of biosafety cabinets on the market, as well as cytotoxic safety cabinets, laminar flow cabinets, weighing hoods, fume hoods and industrial laminar flow installations.
AdGeniX and its partners have the experience and know-how to provide preventive and corrective maintenance for all makes of laminar airflow equipment.
AdGeniX also offers Thermotron Inc’s CDS-5 cytogenetic drying chamber to achieve optimised chromosome spreading for karyotyping and FISH.
Additionally, AdGeniX offers a range of molecular biology reagents, FISH probes and custom cell culture media.
Always at the cutting-edge of innovation in genetic diagnosis, AdGeniX has recently extended its range with the first non-invasive bladder cancer detection test with a sensitivity and specificity equivalent to cystoscopy. The BCA-1 test is derived from patented research by Array Genomics and will shortly be available in Europe for bladder-cancer patients and urologists.
AdGeniX has worked with many trusted partners for over 20 years in order to build innovative synergies in life sciences and healthcare. They include:
All the regional teaching hospitals in France